SAB BIOTHERAPEUTICS, INC. (SABS)

Every figure this model derived for SABS, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 933,156 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 102,632,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 107,937,000 AssetsCurrent 2026-06-30
current liabilities 11,705,000 LiabilitiesCurrent 2026-06-30
equity 214,785,000 StockholdersEquity 2026-06-30
interest expense 231,499 InterestExpenseNonoperating 2026-06-30
ocf -53,937,111 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 0 RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31
sbc 16,677,647 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up SABS on one particular measure came for.

RatioValue
current ratio9.22
current ratio reported9.22
dilution pct563.14
interest cover-310.26
revenue growth-100.0
revenue growth per share-100.0
roic-49.19

What to be careful about

What this model itself distrusts about SABS's figures. Written by the derivation as it ran, not added afterwards.